Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 627

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma

Open access
Hassannia, Behrouz, Wiernicki, Bartosz, Ingold, Irina, Qu, Feng, Van Herck, Simon, Tyurina, Yulia Y., Bayır, Hülya, Abhari, Behnaz A., Angeli, Jose Pedro Friedmann, Choi, Sze Men, Meul, Eline, Heyninck, Karen, Declerck, Ken, Chirumamilla, Chandra Sekhar, Lahtela-Kakkonen, Maija, Van Camp, Guy, Krysko, Dmitri V., Ekert, Paul G., Fulda, Simone, De Geest, Bruno G., Conrad, Marcus, Kagan, Valerian E., Vanden Berghe, Wim, Vandenabeele, Peter, Vanden Berghe, Tom·2018·Journal of Clinical Investigation

Abstract

High-risk neuroblastoma is a devastating malignancy with very limited therapeutic options. Here, we identify withaferin A (WA) as a natural ferroptosis-inducing agent in neuroblastoma, which acts through a novel double-edged mechanism. WA dose-dependently either activates the nuclear factor-like 2 pathway through targeting of Kelch-like ECH-associated protein 1 (noncanonical ferroptosis induction) or inactivates glutathione peroxidase 4 (canonical ferroptosis induction). Noncanonical ferroptosis induction is characterized by an increase in intracellular labile Fe(II) upon excessive activation of heme oxygenase-1, which is sufficient to induce ferroptosis. This double-edged mechanism might explain the superior efficacy of WA as compared with etoposide or cisplatin in killing a heterogeneous panel of high-risk neuroblastoma cells, and in suppressing the growth and relapse rate of neuroblastoma xenografts. Nano-targeting of WA allows systemic application and suppressed tumor growth due to an enhanced accumulation at the tumor site. Collectively, our data propose a novel therapeutic strategy to efficiently kill cancer cells by ferroptosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci99032

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 627

Metadata

Authors
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., Bayır, H., Abhari, B. A., Angeli, J. P. F., Choi, S. M., Meul, E., Heyninck, K., Declerck, K., Chirumamilla, C. S., Lahtela-Kakkonen, M., Van Camp, G., Krysko, D. V., Ekert, P. G., Fulda, S., De Geest, B. G., Conrad, M., Kagan, V. E., Vanden Berghe, W., Vandenabeele, P., & Vanden Berghe, T.
Venue
Journal of Clinical Investigation
Published
2018-06-25
Volume
128
Issue
8
Pages
3341-3355
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2809820903
Cited by
627
References
20
FWCI
29.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. https://app.cochat.ai/papers/10.1172/jci99032
The paper
Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., Bayır, H., Abhari, B. A., Angeli, J. P. F., Choi, S. M., Meul, E., Heyninck, K., Declerck, K., Chirumamilla, C. S., Lahtela-Kakkonen, M., Van Camp, G., Krysko, D. V., Ekert, P. G., Fulda, S., . . . Vanden Berghe, T. (2018). Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci99032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.